Xencor (XNCR) Doses First Patients in Phase 2 Trial of XmAb5871 for IgG4-RD and Phase 2 Trial in SLE

March 7, 2016 4:02 PM

Xencor, Inc. (NASDAQ: XNCR) today announced dosing the first patient in a Phase 2 trial of XmAb®5871 in patients with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found